Reston, Va.—With the most recent release of data from the National Oncologic PET Registry (NOPR), researchers may have reached the moment of critical mass by confirming the effectiveness of positron emission tomography (PET) in the monitoring of tumor activity across a wide range of cancers.
"During the first year of the study, we verified that PET finds more areas of active cancer than other imaging tools and leads, in some cases, to earlier initiation of subsequent treatment," said Bruce E. Hillner, M.D., professor of medicine at Virginia Commonwealth University in Richmond, Va., and lead author of the article. "We noted that PET has a clinically significant impact on cancer management, resulting in a change in treatment in more than one out of three cases—or 36 percent of the time."
In the article, published in the December issue of The Journal of Nuclear Medicine, researchers reported results by cancer type for the first two years of data collected from nearly 41,000 PET studies conducted at more than 1,300 cancer centers nationwide. Analysis was restricted to the use of PET for staging, restaging or detection of suspected recurrences in patients with pathologically proven cancers.
source: SNM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment